Drug intelligence / Profile preview

beta-peltatin

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
None (research Use; Not Approved For Clinical Administration)
01

Overview

**beta-peltatin** is a natural cyclolignan compound (molecular formula C22H22O8, CAS number 518-29-6) isolated primarily from the rhizomes of Podophyllum peltatum (mayapple) and other plant sources. It is structurally related to podophyllotoxin and α-peltatin, sharing the characteristic polycyclic core with methoxy and hydroxy substitutions[1][2][4]. Beta-peltatin possesses notable antitumor and antiviral activity; it acts as a cytotoxic compound and is a known inhibitor of cell division. Its mechanism of action is believed similar to other podophyllotoxin derivatives: inhibition of microtubule assembly via binding to tubulin, leading to mitotic arrest, and possibly some inhibition of DNA topoisomerase II, though direct evidence for topoisomerase II binding is less than for some derivatives[3][5]. Beta-peltatin has been studied in vitro for cytotoxic, antitumor, and antiviral properties but has not been developed as a marketed pharmaceutical[3][5]. It serves as a chemically interesting compound for the synthesis and study of podophyllotoxin-related anticancer agents.

Other names
(5R,5aR,8aR)-10-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one8-hydroxy-2-hydroxymethyl-6,7-methylenedioxy-4-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydronaphthalene-3-carboxylic acid lactoneβ-Peltatin A
02

Targets

TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on beta-peltatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-peltatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call